Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 Nasopharyngeal Carcinoma: A Multicenter, Randomized Controlled, Phase III Clinical Study

NCT07248670 is registered in ClinicalTrials.gov with Chongqing University Cancer Hospital as lead sponsor.

NCT NCT07248670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07248670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 Nasopharyngeal Carcinoma: A Multicenter, Randomized Controlled, Phase III Clinical Study
Lead sponsor
Chongqing University Cancer Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 4, 2025
Completion date
December 31, 2031
Enrollment
252 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancinoma (npc)